DISCLAIMER: This is an unofficial English translation of an original document in Spanish and is provided for information purposes only. In case of any discrepancy between this translation and the original Spanish text, the Spanish version shall prevail.

TO BME GROWTH

Barcelona, 14 March 2025

Pursuant to article 17 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April, on market abuse, and article 228 of the consolidated text of the Law on Market Securities and Investment Services, approved by Royal Legislative Decree 6/2023 of 17 March and its concordant provisions, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, Holaluz-Clidom, S.A. ("**Holaluz**", the "**Firm**" or the "**Company**") hereby discloses the following

INSIDER INFORMATION

As a continuation of the privileged information communicated by the Company to the market on 4 November 2024 and on 14 March 2025, Holaluz informs that, within the framework of ICOSIUM Investment, S.L. ("**ICOSIUM**") investment in the Company, the first planned phase has been completed.

The Board of Directors of the Company, exercising the delegation conferred by the extraordinary general shareholders' meeting of the Company held on 9 November 2021, at its meeting on 24 October 2024 approved a capital increase of the Company with exclusion of pre-emptive subscription rights, with an aggregate nominal amount of €108,000 and an aggregate share premium of €6,372,000, representing an aggregate effective amount (nominal value plus share premium) of €6,480,000 (the "**Capital Increase**").

After ICOSIUM fully subscribed and paid up all the capital, today the Capital Increase has been executed through the issuance and circulation of 3,600,000 new ordinary shares of the Company, of the same class and series as those currently in circulation, represented by book entries (the "**New Shares**"). The New Shares are issued at their unit nominal value of €0.03 plus a share premium of €1.77 per share, resulting in an effective issue price of €1.80 per share. The New Shares represent 16.45% of the share capital before the Capital Increase and 14.12% of the Company's share capital after the Capital Increase, and their admission to trading on the BME Growth Market will be requested.

The net funds from the Capital Increase have been injected by ICOSIUM into the Company in order to allow it to stabilise existing debt obligations with suppliers; strengthen the Company's cash position to finance daily working capital; and improve the company's operational platform for natural gas and other green energies.

As a result of the Capital Increase, Holaluz's share capital has been set at €764,661.57, divided into 25,488,719 shares with a nominal value of €0.03 each, all belonging to a single class and series.

Consequently, following the complete subscription, disbursement and closing of the Capital Increase, the shareholders who have a direct or indirect stake exceeding 5% of the Company's share capital are:

Shareholder	Participation in the share capital (%)
Fondo Axon ICT III, F.C.R.	14.43%
Icosium Investment, S.L.	14.12%
D. Ferran Nogué Collgros	12.60%
D.ª Carlota Pi Amorós	12.60%
D. Oriol Vila Grifoll	12.59%
Geroa Pentsioak E.P.S.V. de Empleo	5.74%

The Company is not aware of the existence of other shareholders with direct or indirect stakes exceeding 5% of the share capital.

In compliance with the provisions of the BME MTF Equity Circular 3/2020, it is expressly stated that the information provided has been prepared under the exclusive responsibility of the Company and its directors.

Carlota Pi Amorós
coFounder and President
HOLALUZ-CLIDOM, S.A